Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DBV Technologies
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
- Medical Devices
In Vitro Diagnostics
- Chemistry, Immunoassay
- Large Molecule
Drug Discovery Tools